Personal Genome Diagnostics And Cleveland Diagnostics Will Use New Funding To Expand Cancer Portfolios
Executive Summary
Personal Genome Diagnostics will use its funding to expand its liquid biopsy portfolio. Cleveland Diagnostics plans to develop early detection tests for lung and breast cancer.
You may also be interested in...
Minute Insight: Quidel And Labcorp Finish Big Year For IVD Deals With Major Acquisitions
Quidel will pay $6bn for Ortho Clinical Diagnostics. Labcorp will acquire Personal Genome Diagnostics for $575m.
JPM 2022: Boston Scientific, Inspire, Nuvasive, Vericel
The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022 as they continue to cope with the impact of the Omicron surge. Here are some of the highlights from the presentations on the third day of the meeting.
JPM 2022: Abbott, iRhythm, Novocure, Zimmer Biomet
The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022 as they continue to cope with the impact of the Omicron surge. Here are some of the highlights from the presentations on the second day of the meeting.